There is no proven mushroom treatment for seizures in humans, but early research on several mushroom species shows intriguing effects on brain inflammation and nerve cell survival that are relevant to epilepsy. The picture is complicated: some mushrooms show protective potential in animal studies, while others, particularly psychedelic mushrooms taken at high doses, have triggered seizures in people with epilepsy. Here’s what the science actually shows so far.
Medicinal Mushrooms With Anti-Seizure Potential
Several non-psychedelic mushroom species have been studied in laboratory and animal models for their effects on the brain, and a few stand out for epilepsy-related research.
Lion’s Mane
Lion’s mane contains bioactive compounds, including one called erinacine A, that can cross into the brain and reduce inflammation. In a mouse study using a common seizure model, lion’s mane extract given for 21 days significantly improved the survival of neurons in the hippocampus, the brain region most vulnerable to seizure damage. The extract worked by lowering levels of an inflammatory enzyme in brain cells, essentially dialing down the destructive inflammation that follows a seizure.
Interestingly, dose mattered in a non-obvious way. The low and mid-range doses (60 and 120 mg/kg) protected neurons, while the highest dose (300 mg/kg) offered no more protection than a placebo. This is a pattern researchers sometimes see with natural compounds, where more is not necessarily better.
Reishi
Reishi mushroom spores have shown antiepileptic properties in both cell and animal studies. The spores appear to work through several pathways: promoting the survival of neurons, inhibiting calcium buildup in brain cells (calcium overload is one trigger for seizure activity), and reducing abnormal nerve fiber growth in the hippocampus. In one small human observation, daily intake of 1,000 mg of reishi spore powder three times a day for eight weeks was associated with reduced weekly seizure frequency in people with epilepsy. That finding is promising but far from conclusive, as it hasn’t been replicated in a controlled clinical trial.
Maitake and Ear Mushroom
Maitake mushroom polysaccharides have been studied for their prebiotic effects on gut bacteria, which is relevant because the gut-brain connection plays a role in seizure control. These complex sugars are broken down by gut bacteria into active compounds that can influence inflammation, neurotransmitter levels, and even ion channels in the brain. Separately, extracts of the ear mushroom have reduced seizure activity in mice at doses of 400 to 600 mg/kg in a dose-dependent pattern, meaning higher doses had a stronger effect.
The Gut-Brain Connection
One of the more promising lines of research involves mushroom polysaccharides, the complex carbohydrates found in virtually all edible mushrooms. These compounds act as prebiotics, feeding beneficial gut bacteria that in turn produce metabolites influencing brain function. Polysaccharides can repair the intestinal barrier, shift the composition of gut bacteria, and regulate inflammatory signaling molecules. Since gut microbiome imbalances have been linked to seizure susceptibility, this indirect pathway could partially explain why certain mushrooms show antiepileptic effects in animal models, even though the active compounds don’t necessarily reach the brain directly.
Psychedelic Mushrooms and Seizure Risk
Psilocybin mushrooms are a different story entirely, and the evidence here is mixed in a way that should give anyone with epilepsy serious pause. No clinical trial or preclinical seizure model has demonstrated that psychedelics reliably induce seizures in healthy people. Poison control data shows seizures occur in less than 1% of reported psilocybin cases (0.78% of nearly 5,900 cases). But for people who already have epilepsy, the risk profile looks different.
The most detailed case involves a man with treatment-resistant temporal lobe epilepsy who had a brain-implanted device that continuously recorded his seizure activity. After consuming an estimated 2.5 to 3.0 grams of dried psychedelic mushrooms (roughly 20 mg of psilocybin), his device recorded 32 prolonged episodes of seizure-like brain activity in a single day. His typical baseline was zero to two episodes per day. When he later took a lower dose of about 1.5 grams (roughly 10 mg of psilocybin), his seizure activity didn’t change from baseline. This is the first case where psychedelic-associated seizures were confirmed with direct brain recordings.
In a broader survey of 613 people who had used psychedelics, nine reported associated seizures. Five of those nine had a personal history of epilepsy, and seven had a family history. The pattern suggests that people with existing seizure disorders or genetic predisposition face a meaningfully higher risk.
Adding to the complexity, some case reports describe seizure remission following psychedelic use, and confounding factors like alcohol consumption or other medications make it hard to attribute outcomes solely to psilocybin. The overall trend in reviews is that psychedelics appear safe in controlled, supervised settings for people without epilepsy, but the data for people with seizure disorders is too thin and contradictory to draw conclusions.
Toxic Mushrooms That Cause Seizures
Some wild mushrooms are genuinely dangerous for brain function. Amanita muscaria, the iconic red-capped mushroom, contains ibotenic acid and muscimol, two compounds that are structurally similar to key brain signaling molecules. Ibotenic acid stimulates excitatory receptors in the brain (the same type involved in seizure generation), while muscimol acts on inhibitory receptors. These two compounds convert back and forth into each other in the body, causing unpredictable swings in brain activity. Both cross the blood-brain barrier rapidly after ingestion. Accidental poisoning with Amanita species can cause neurological symptoms ranging from confusion to convulsions.
What This Means in Practice
No mushroom species has been validated as a seizure treatment in humans through clinical trials. The most encouraging evidence comes from lion’s mane and reishi in animal models, where specific doses protected brain cells from seizure-related damage and, in reishi’s case, possibly reduced seizure frequency. These findings are early-stage and don’t translate into reliable dosing recommendations for people.
For anyone with epilepsy considering mushroom supplements, the research on lion’s mane and reishi suggests potential neuroprotective benefits, but the dose-dependent effects seen in animal studies highlight that getting the amount right matters. The lion’s mane research in particular showed that too high a dose eliminated the protective effect entirely. Mushroom supplements also vary widely in their actual content of bioactive compounds depending on whether they’re made from the fruiting body, mycelium, or spores.
Psychedelic mushrooms carry a documented risk of worsening seizures in people with epilepsy, particularly at higher doses. The case with direct brain recordings showed a dramatic, dose-dependent spike in seizure activity that returned to baseline at a lower dose, suggesting the risk scales with the amount consumed. Until controlled studies specifically examine psilocybin in people with seizure disorders, the safest assumption is that it’s an unpredictable variable for anyone managing epilepsy.